We have evaluated the perioperative effects of melatonin with those of midazolam in 75 women in a prospective, randomized, double-blind, placebo-controlled study. Patients were given sublingual midazolam 15 mg, melatonin 5 mg or placebo, approximately 100 min before a standard anaesthetic. Sedation, anxiety and orientation were quantified before, and 10, 30, 60 and 90 min after premedication, and 15, 30, 60 and 90 min after admission to the recovery room. Psychomotor performance was evaluated at these times also, using the digit-symbol substitution test (DSST) and the Trieger dot test (TDT). Patients who received premedication with either midazolam or melatonin had a significant decrease in anxiety levels and increase in levels of sedation before operation compared with controls. Midazolam produced the highest scores for sedation at 30 and 60 min after administration and significant psychomotor impairment in the preoperative period compared with melatonin or placebo. After operation, patients who received midazolam or melatonin premedication had increased levels of sedation at 30 min and impairment in performance on the DSST at 15, 30 and 90 min compared with controls. There were no significant differences between the three groups for anxiety levels or TDT performance after operation. Amnesia was notable only in the midazolam group for one preoperative event (entry into the operating room). Patient satisfaction was noted in the midazolam and melatonin groups only. We have demonstrated that melatonin can be used effectively for premedication of adult patients. 1999; 82: 875-80 
The pineal hormone melatonin (N-acetyl-5-methoxytryptamine) has several putative functions, including regulation of circadian rhythms, 1 regulation of the reproductive axis 2 and antioxidant activity. 3 Autoradiographic studies and receptor assays have demonstrated the presence of melatonin receptors in various regions of the central nervous system and in other tissues in humans. 4 Exogenous administration of melatonin has been found by several investigators to facilitate sleep onset and improve quality of sleep. 5 6 Available data suggest that the sleepinducing properties of melatonin may differ from those of benzodiazepines. Benzodiazepines decrease duration of REM sleep after single administration of a high dose 7 or long-term administration of a low dose. 8 Benzodiazepines also reduce slow-wave sleep, 9 thus negatively influencing sleep quality. In contrast, a single low dose of melatonin produced no suppression of REM sleep. 10 Furthermore, unlike benzodiazepines, melatonin does not induce 'hangover' effects. 10 
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Oral melatonin 5 mg daily has been used to alleviate jet lag and tiredness after long flights 11 and for treatment of sleep disorders in blind subjects 12 13 and in patients with delayed phase sleep syndrome. 12 13 Therefore, we selected a 5-mg dose of melatonin for this study.
To our knowledge, the use of melatonin in anaesthesia has never been evaluated previously. This prospective, randomized, double-blind, placebo-controlled study was designed to compare the effect of sublingual melatonin with that of sublingual midazolam as premedication. The sedative, anxiolytic and amnesic effects of both drugs in addition to the residual effects in the immediate postoperative period were evaluated.
Patients and methods
After obtaining institutional approval and informed consent, we studied 75 ASA I women, aged 19-44 (mean 29.7) yr, weighing 41-87 (mean 67.2 (SD 11)) kg, under-going gynaecological laparoscopic procedures. No patient was pregnant or lactating, abusing centrally acting drugs, consuming monoamine oxidase inhibitors or allergic to the drugs under study. The day before surgery, a psychologist explained to the patient the study plan and the different scales used in the assessment.
Approximately 2 h before surgery, patients were transported to an isolated quiet room in the operating suite. A pulse oximeter probe was placed on all patients and Sp O 2 , arterial pressure and heart rate were recorded continuously. Resuscitative equipment was available at the bedside. Patients were allocated randomly to one of three groups (nϭ25 in each). The midazolam group received sublingual midazolam 15 mg using a 0.5% ampoule solution originally intended for i.v. use (Dormicum, Roche). The melatonin group received sublingual melatonin 5 mg (colloidal melatonin, Innovative Natural Products, Escondido, CA 92025, USA). The control group received sublingual placebo (saline). Study drugs and placebo were prepared in a fixed volume of 3 ml (in a syringe from which the needle had been removed) and marked only with a coded label to maintain the double-blind nature of the study. The content of the syringe was given sublingually approximately 100 min before induction of general anaesthesia by a resident not involved in the management of the patient or in data collection. The patient was first asked to place the tip of the tongue to the back of the upper teeth. The drug was then placed under the tongue, the patient was asked to close their mouth, and was instructed 'Don't swallow!'; at 180 s, the patient was permitted to swallow the medication. We did not add any flavour to midazolam as it has been reported that addition of candy flavour did not improve acceptance of or compliance with sublingual midazolam administration. 14 A visual analogue scale (VAS) was used to evaluate anxiety. The scale is a 50-cm long and 10-cm high card, divided diagonally into white and bright red triangles. The centimetre scale was on the rear side of the card. 15 16 The extremes were marked 'no anxiety' at the white end and 'anxiety as bad as ever can be' at the red end. The same psychologist blinded to group assignment performed all test scoring and calculations. The psychologist evaluated anxiety VAS, orientation score (0ϭnone; 1ϭorientation in either time or place; 2ϭorientation in both) and sedation score (1ϭawake; 2ϭdrowsy; 3ϭasleep, but arousable; 4ϭasleep, but not arousable) before, and 10, 30, 60 and 90 min after administration of premedication, and after operation at 15, 30, 60 and 90 min after admission to the recovery room. In addition, patients were asked to perform the digit-symbol substitution test (DSST) 17 18 and Trieger dot test (TDT) 19 at these times. The DSST forms part of the performance scale of the Wechsler adult intelligence test. These tests were used to quantitatively assess psychomotor activity.
All patients were positioned with 30°head elevation and used the same writing implement (ballpoint pen, medium point, black) for all tests. The DSST score represented the number of correct symbol substitutions made in 60 s and 876 the score was normalized according to a table (the normalized DSST or NDSST score). The TDT score represented the total number of missed dots (out of 42) connected. TDT deviation represented the cumulative shortest distance (in mm) between the drawn line and missed dots. The time to perform the TDT was measured in seconds using a stopwatch. To account for inter-patient differences in testtaking ability, anxiety VAS, NDSST and TDT scores, TDT deviations and time to perform TDT test were normalized to baseline scores, deviation and time for each patient. Changes in scores of different tests and TDT deviation and TDT time relative to baseline values were compared.
Amnesia was assessed by showing patients two simple line diagrams before premedication. Patients were queried 24 h later as to recall of the diagrams, entry into the operating room and i.v. catheter insertion in the operating room.
In the operating room, an infusion of lactated Ringer's solution was commenced. Anaesthesia was induced with fentanyl 1 µg kg -1 , propofol 2 mg kg -1 and mivacurium 0.2 mg kg -1 . After tracheal intubation, anaesthesia was maintained with isoflurane and 70% nitrous oxide in oxygen, supplemented with fentanyl. End-tidal concentrations of oxygen, nitrous oxide and carbon dioxide were measured continuously by a multiple-gas analyser (Capnomac, Datex Instrumentarium Corporation, Helsinki, Finland). Ventilation was adjusted to maintain normocapnia (end-tidal carbon dioxide partial pressure 4.7-5.3 kPa). Haemoglobin oxygen saturation was monitored by pulse oximetry. Temperature was monitored by a nasopharyngeal thermistor and was maintained at 36.5Ϯ0.5°C. Neuromuscular function was monitored by a peripheral nerve stimulator. Surgery time (incision to surgery end) and anaesthesia time (induction to emergence) were recorded. In the recovery room, postoperative pain was quantitated using a 100-mm VAS, and was assessed at 15, 30, 60 and 90 min after arrival in the recovery room. Postoperative pain was treated with incremental doses of morphine i.v. and the total dose administered was noted. Postoperative nausea and vomiting were treated with ondansetron 4 mg i.v. On the second day, patients were questioned about their premedication: 'Was the premedication satisfactory or not' and 'If needed would they prefer the same or another premedication in future'.
Statistical analysis
With a sample size in each of the three groups of 21, a 0.05 level chi-square test has 90% power to detect a difference in proportions characterized by a variance of proportions (VϭΣ(π I -π 0 ) 2 /G) of 0.047 and an average proportion of 0.347. This was based on the assumption that placebo would have an effect in 4% of patients whereas both midazolam and melatonin would have an effect in at least 50% of patients. However, if the assumption was made that the study drugs would have an effect in a greater proportion of patients (Ͼ50%), the sample size would have been smaller.
Statistical analysis was performed using the Kruskal- 
Results
Patients in the three groups were comparable in age, weight, height, surgery time and anaesthesia time ( Table 1 ). Figure 1 shows a significantly (PϽ0.05) greater effect of both midazolam and melatonin compared with placebo for pre-877 operative anxiety VAS. However, there were no differences in anxiety VAS between the groups after operation. At 30 min after premedication, sedation was evident only in the midazolam group (Table 2) . Patients who received midazolam and melatonin showed increased levels of sedation at 60 and 90 min (PϽ0.001) after premedication compared with the placebo group (Table 2) . Furthermore, patients in the midazolam group showed significantly (PϽ0.05) higher levels of sedation compared with the melatonin group at 30 and 60 min after premedication (Kruskal-Wallis test). After operation, there was no difference in the level of sedation between groups except at 30 min where patients in the midazolam and melatonin groups showed an increased level of sedation (Pϭ0.016) compared with the placebo group ( Table 2) .
The mean dose of fentanyl administered in the intraoperative period was similar between groups (105 (41), 106 (39) and 105 (30) µg for the midazolam, melatonin and placebo groups, respectively). Neither postoperative pain scores nor morphine consumption were different between the groups at any time during their stay in the recovery room. The number of patients requiring one or more injections of morphine in the recovery room was eight, seven and five in the midazolam, melatonin and placebo groups, respectively. Cumulative morphine consumption during recovery room stay was 53, 46.5 and 42 mg for the midazolam, melatonin and placebo groups, respectively.
Orientation scores were similar, except at 30 min after premedication. At that time, only 18 (72%) patients in the midazolam group were orientated in both time and place compared with 24 (96%) and 22 (88%) patients in the melatonin and placebo groups, respectively (Pϭ0.012).
There were no differences between the midazolam, melatonin and placebo groups in baseline NDSST score (10 (3), 9 (2) and 9 (2), respectively), TDT score for missed dots (12 (7), 14 (7) and 11 (8) , respectively), TDT deviation (4 (3), 4 (3) and 5 (5) mm, respectively) or TDT time (13 (6), 14 (6) and 13 (4) s, respectively). Ten minutes after administration of premedication, patients in the midazolam group had significantly poorer performance on both tests compared with the melatonin and placebo groups (Figs 2,  3 ). There was no difference in the time needed to perform the TDT test between groups. In the recovery room, the placebo group performed the DSST significantly better at 15, 30 and 90 min than the other two groups (Fig. 2) . However, there was no difference in TDT score, deviation or time between the three groups in the recovery room. Patients who were deeply sedated (asleep, but not arousable; Table 2 ) were unable to perform the DSST and TDT and were not included in the statistical analysis.
In the melatonin group, at 24 h one patient did not recall the two simple line diagrams and a second patient recalled only one diagram. All other patients in the three groups recalled the two diagrams (Fig. 4) . Patients who received midazolam had a higher incidence of amnesia for one preoperative event only (entry into the operating room) ( Fig. 4) . Twenty-three patients (92%) in the midazolam group and 22 patients (88%) in the melatonin group were satisfied with their premedication. In the placebo group, 878 17 patients (68%) (Pϭ0.055) were satisfied with their premedication. All patients in the midazolam and melatonin groups stated they would prefer to have the same premedication and 14 patients (56%) in the placebo group said they would prefer another premedicant in future. One patient in the melatonin group who had midazolam premedication for a previous surgery several months earlier (and was not included in the midazolam group in this study) indicated that she would prefer to have melatonin (rather than midazolam) premedication in future. No side effects were noted.
Discussion
We have demonstrated that patients who received premedication with either sublingual midazolam 15 mg or sublingual melatonin 5 mg had a significant decrease in anxiety levels and increase in levels of sedation before operation compared with patients who received placebo. However, in the preoperative period, only patients in the midazolam group experienced significant impairment of psychomotor skills. After operation, patients who received midazolam or melatonin premedication had increased levels of sedation at 30 min and impairment of performance on the DSST at 15, 30 and 90 min compared with controls. However, there were no significant 879 differences between the three groups for anxiety levels or TDT performance in the postoperative period. Amnesia was notable only in the midazolam group for one preoperative event.
Before operation, DSST and TDT scores, and TDT deviation improved in the melatonin and control groups 10 min after administration of melatonin and saline, respectively. This reflects learning behaviour in these groups. In contrast, significant impairment in performance on the DSST and TDT relative to baseline was noted in the midazolam group. These findings are consistent with other studies of psychomotor effects produced by midazolam premedication. 20 21 The decreased number of errors on the DSST and TDT tasks noted after administration of melatonin is somewhat surprising as one might expect errors to increase after administration of a substance with sedativelike properties. However, it has been shown that administration of large doses of melatonin (240 mg divided into three doses) to volunteers did not impair either fine motor performance or tests of memory and visual sensitivity. 22 The onset and peak effect of midazolam-induced sedation were noted at 30 and 60 min, respectively, after sublingual administration. Other investigators have reported similar observations. 23 Although seven patients (28%) were asleep 30 min after administration of melatonin, the onset of significant levels of sedation and the peak effect were delayed in this group (60 and 90 min, respectively). Furthermore, patients in the midazolam group showed significantly (PϽ0.05) higher levels of sedation compared with the melatonin group at 30 and 60 min after premedication. It should be noted, however, that despite substantial impairment of performance on the DSST and TDT, and substantial sedation after midazolam premedication before operation, there were no significant differences between the midazolam and melatonin groups after operation. This finding could not be accounted for by differences in duration of surgery, duration of anaesthesia or total number of cumulative doses of morphine administered in the recovery room. Other investigators noted that premedication with midazolam was associated with preoperative anxiolysis, sedation and impairment of psychomotor skills without affecting the quality of recovery or discharge time after ambulatory surgery. 20 24 Although we did not observe any difference between the three groups in TDT performance after operation, the placebo group performed the DSST significantly better at 15, 30 and 90 min compared with the two other groups. Similarly, others 20 25 observed that the DSST was more sensitive than the TDT for detection of psychomotor/ cognitive impairment. Tsai and colleagues 25 noted that several of their patients (after recovery from isoflurane anaesthesia) stated that they perceived distortion of the symbols and numbers of the DSST even after they had managed to pass the TDT. It appears that the DSST is a more sensitive test than the TDT for detection of residual cortical depression and can be used as an indicator of the progress of recovery.
The amnesic properties of the benzodiazepines have been well studied in adults. Benzodiazepines impair acquisition of new information with no effect on retention or retrieval of previously stored information. 26 In this study, midazolam diminished anterograde recall for one preoperative event compared with the melatonin and placebo groups. Our results indicate that melatonin had no amnesic effects.
